Sartore-Bianchi A - Search Results

1

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases.

Giannini V, Pusceddu L, Defeudis A, Nicoletti G, Cappello G, Mazzetti S, Sartore-Bianchi A, Siena S, Vanzulli A, Rizzetto F, Fenocchio E, Lazzari L, Bardelli A, Marsoni S, Regge D. Giannini V, et al. Cancers (Basel). 2022 Jan 4;14(1):241. doi: 10.3390/cancers14010241. Cancers (Basel). 2022. PMID: 35008405 Free PMC article.

2

Controversies in the management of brain metastases: the role of chemotherapy.

Landonio G, Sartore-Bianchi A, Giannetta L, Renga M, Riva M, Siena S. Landonio G, et al. Forum (Genova). 2001 Jan-Mar;11(1):59-74. Forum (Genova). 2001. PMID: 11734865 Review.

3

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Moroni M, et al. Lancet Oncol. 2005 May;6(5):279-86. doi: 10.1016/S1470-2045(05)70102-9. Lancet Oncol. 2005. PMID: 15863375 Clinical Trial.

4

Cetuximab for treatment of metastatic colorectal cancer.

Cerea G, Ricotta R, Schiavetto I, Maugeri MR, Sartore-Bianchi A, Moroni M, Artale S, Siena S. Cerea G, et al. Ann Oncol. 2006 Jun;17 Suppl 7:vii66-7. doi: 10.1093/annonc/mdl954. Ann Oncol. 2006. PMID: 16760297 Free article.

5

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Benvenuti S, et al. Cancer Res. 2007 Mar 15;67(6):2643-8. doi: 10.1158/0008-5472.CAN-06-4158. Cancer Res. 2007. PMID: 17363584

6

Rationale and clinical results of multi-target treatments in oncology.

Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S. Sartore-Bianchi A, et al. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S77-87. Int J Biol Markers. 2007. PMID: 17520585 Review.

7

EGFR FISH in colorectal cancer: what is the current reality?

Moroni M, Sartore-Bianchi A, Veronese S, Siena S. Moroni M, et al. Lancet Oncol. 2008 May;9(5):402-3. doi: 10.1016/S1470-2045(08)70109-8. Lancet Oncol. 2008. PMID: 18452847 No abstract available.

8

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Di Nicolantonio F, et al. J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001320 Free article.

9

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Sartore-Bianchi A, et al. Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223544

10

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Siena S, et al. J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. J Natl Cancer Inst. 2009. PMID: 19738166 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters